CATTI opens a cell and gene therapy training centre of excellence at the University of Guelph

The Canadian Advanced Therapies Training Institute (CATTI) Inc. has launched its first in-person training site at the University of Guelph through a partnership with OmniaBio Inc., CCRM and the university. The training program, to begin in summer 2023, will cater to recent post-secondary graduates, industry professionals and companies growing their roster of clean room manufacturing staff. The fast growth of cell and gene therapies (CGTs) has made it a challenge for the global industry to keep up with talent requirements. This new CGT technical training site will begin to address the industry's critical training needs and represents the first stage of a larger, multi-site training strategy for CATTI.

NewsGuest UserMay 24, 2023BIOOQuébecCATTI, Canadian Advanced Therapies Training Institute, University of Guelph, OmniaBio, CCRM

CCRM and Amgen partner to advance emerging medical innovations

TORONTO and MISSISSAUGA, ON, April 29, 2021 /CNW/ - New regenerative medicine discoveries, including cell and gene therapies, will never reach patients without access to the funding, expertise and other specialized support that are required to move along the commercialization pathway. To address this need, CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies, and Amgen, a global leader in the biotechnology industry, are announcing a multi-year fund, for early-stage regenerative medicine-based technologies and therapies to benefit patients and the health-care system. The collaboration is made up of equivalent investments from CCRM and Amgen.

NewsGuest UserApril 29, 2021CCRM, Amgen, medical innovations